Q3 FY2026 · ended Jun 30, 2026 · Revenue $14.36M, -21.6% YoY · Filed Aug 12, 2026
Enanta Pharmaceuticals, Inc (ENTA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $14.4 million and a net loss of $19.5 million. Free cash flow was -$10.0 million. As of Jun 30, 2026 it held $211.5 million in cash and investments and $55.7 million in total debt.
Revenue
$14.36M
-21.6% vs year-ago quarter
Net income
$-19.50M
-6.8% vs year-ago quarter
Operating cash flow
$-9.97M
-157.0% vs year-ago quarter
Free cash flow
$-9.98M
-157.5% vs year-ago quarter
EPS
$-0.67
+21.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
29.13M
+36.2% vs year-ago quarter
Net cash
$155.84M
Q3 FY2026
Operating margin
-90.0%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ENTA (Nasdaq)
- Fiscal year ends
- September 30
- Headquarters
- Watertown, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1177648
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Jun 30, 2026 |
Q2 FY2026 Mar 31, 2026 |
Q1 FY2026 Dec 31, 2025 |
Q4 FY2025 Sep 30, 2025 |
Q3 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $14.4M | $17.2M | $18.6M | $15.1M | $18.3M |
| Operating income | -$17.2M | -$11.9M | -$11.3M | -$18.4M | -$18.9M |
| Net income | -$19.5M | -$13.1M | -$11.9M | -$18.7M | -$18.3M |
| Diluted EPS | -$0.67 | -$0.45 | -$0.42 | $0.30 | -$0.85 |
| Operating cash flow | -$10.0M | -$7.2M | -$11.7M | -$6.5M | $17.5M |
| Free cash flow | -$10.0M | -$7.2M | -$11.8M | -$7.9M | $17.4M |
| Total assets | $296.9M | $314.7M | $329.5M | $280.7M | $301.0M |
| Total liabilities | $195.8M | $198.1M | $202.9M | $216.0M | $221.8M |
| Stockholders' equity | $101.1M | $116.6M | $126.6M | $64.7M | $79.3M |
| Cash and investments | $211.5M | $227.0M | $241.9M | $188.9M | $204.1M |
| Total debt | $55.7M | $56.5M | $57.1M | $57.9M | $58.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 28, 2026 | Oct 28, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 2, 2026 | Jul 2, 2026 |
| 8-K |
Current report
Other events
|
Jun 23, 2026 | Jun 23, 2026 |
All 835 Enanta Pharmaceuticals, Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.